Aridis Pharma soars on promising data from anti-viral drug

Aridis Pharmaceuticals

21/12/2021 10:54

** Shares of biopharma co  ARDS.O  up ~108% at $5.29
premarket, set to open at their highest in nearly five months
    ** Stock among top percentage gainers across U.S. exchanges
    ** Co says its fully human monoclonal antibody cocktail,
AR-701, is broadly reactive against the Omicron and other
COVID-19 variants  urn:newsml:reuters.com:*:nPn4LWQDma 
    ** AR-701 is also reactive against SARS (Severe Acute
Respiratory Syndrome), MERS (Middle East Respiratory Syndrome
Coronavirus), and seasonal ('common cold') human coronaviruses
    ** In vivo data on multiple animal models used to evaluate
COVID-19 treatments support AR-701's broad efficacy - co
    ** Up to Monday's close, stock had fallen 58.15% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))